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background: Current recommendation is for ≥ 12 months dual antiplatelet therapy (DAPT) after drug-eluting stents (DES). Patients with diabetes 
mellitus (DM) have higher incidence of thrombotic events after DES compared to non-diabetics. Still, the optimal DAPT duration with specific 
DES type remains unknown. Our objective was to assess the clinical impact of short- (3 months) versus long-term (12 months) DAPT in patients 
undergoing percutaneous coronary intervention (PCI) with the 2nd generation DES Endeavor zotarolimus-eluting stents (E-ZES).
Methods: The OPTIMIZE trial was a randomized (1:1), active-controlled, open-label non-inferiority study including 3,119 patients in 33 sites in 
Brazil between April/2010-March/2012. After PCI with E-ZES, patients were prescribed aspirin 100-200mg daily and clopidogrel 75mg for 3 months 
(n=1,563) or 12 months (n=1,556) DAPT. Clinical follow-up was performed at 1, 3, 6 and 12 months. The 1ary endpoint was net adverse clinical 
and cerebral events (NACCE), a composite of all-cause death, MI, stroke, or major bleeding at 1 year follow-up. Stent thrombosis (ST) was defined 
according to the Academic Research Consortium. Overall, 35% of patients had DM and randomization was stratified by its presence. Also, a DM 
subgroup analysis was pre-specified in the protocol.
results: Considering 1,103 patients with DM at 3 months (n=554) vs. 12 months (n=549) DAPT, mean age was 62.1 vs. 61.7 yrs (p=0.52), female 
gender 44% vs. 47% (p=0.08), prior MI 38% vs. 32% (p=0.04), renal insufficiency 11% vs. 6% (p=0.003), and clinical presentation of unstable 
angina (19% vs. 18%, p=0.53) or non-ST MI (5% vs. 6%, p=0.49), for 3 vs. 12 months groups, respectively. At 12 months, there were comparable 
rates of NACCE (6.3 vs. 6.9%, [difference -0.68, 95% confidence interval (CI) -3.65, 2.29], p=0.65] and definite/probable ST (1.7 vs. 1.1%, [dif. 
0.53, 95% CI -0.87, 1.93], p=0.46), for 3 vs. 12 months, respectively. 
conclusions: In this pre-specified subgroup analysis of the OPTIMIZE trial, short-term DAPT did not significantly increase risk for clinical events at 
1 year in patients with DM undergoing PCI with a specific 2nd generation DES. 
